- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04837248
Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer
Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer Surgery. A Clinical Trial.
Breast cancer surgery usually results in reduced range of motion of the shoulder joint, weakness of the musculature and altered scapular kinematics during movement. These factors limit activities of daily living, so rehabilitation exercises help to restore function after shoulder surgery.
Women with breast cancer often have a life conditioned by the sequelae or morbidity secondary to the treatment of the disease and, despite the high cure rate, many patients are unable to regain their initial quality of life. Cancer therapies can leave physical, psychological and psychosocial sequelae, which may manifest themselves or persist even years after the end of treatment.
For all these reasons, patients who have undergone cancer treatment need physical rehabilitation as well as psychological and social care to support them in their new stage of life, and to optimise the rehabilitation programme, it is necessary to identify each patient's individual needs,
The digital support proposed in this study enables the development of a physiotherapy programme for patients with breast cancer in a situation of health crisis, which includes providing assistance, information, accompaniment, help and treatment to these patients in a comprehensive way, based on the biopsychosocial model.
Study Overview
Status
Conditions
Detailed Description
DESIGN: Single-centre, assessor-blinded, parallel-group, randomised controlled clinical trial.
METHODS: The study will be carried out at the Ramon y Cajal hospital with 92 patients diagnosed and operated on for breast cancer.
Patients who come to the consultation of the rehabilitation doctors will be assessed, considering the inclusion and exclusion criteria. Those who may be candidates will be informed about the study and referred to the physiotherapy department where the treatment orders for these patients will be received and an appointment will be made. This is the start of the recruitment phase.
Those who meet the criteria and agree to participate in the study will be assigned an identification code and will be randomised into the two groups, the intervention group and the conventional treatment group.
Patients who do not meet the inclusion criteria or refuse to participate in the study will receive conventional treatment.
A 6-month pilot study will be conducted to better define patient identification, inclusion criteria, recruitment and adjustment of the intervention if required.
Once the pilot study is completed, the intervention clinical trial will begin. A first analysis of all variables will be performed after the intervention phase of the trial, 6 weeks after inclusion in the study.
An interim analysis will also be performed at 3 months in which the same variables as at 6 weeks will be assessed. This will be the main analysis of the study.
The final analysis will be carried out 6 months after inclusion in the study, and this will conclude the follow-up phase.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28834
- Fundacion Hospital Ramón y Cajal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of stage I, II or III of Breast cancer treated by surgery.
- Medical authorisation for participation.
- Internet access.
- Basic computer skills.
- Signed informed consent.
- No bilateral mastectomy.
- No metastases.
- Post-intervention period of 10 days to 3 months.
- Age 18-85 years.
- No previous shoulder pathologies.
- No pathology that prevents exercise.
- Understanding of the Spanish language.
Exclusion Criteria:
- Breast cancer treated without surgery.
- Patient in severe psychiatric treatment who may present difficulties for participation in the study.
- Stage IV cancer.
- Any other clinical condition or previous therapy that contraindicates one or more of the techniques included in the programme, as the intervention may not be safe for the patient and therefore the person would not be eligible to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group 1. Conventional treatment
Patients will be treated with a physiotherapy programme without digital support.
|
Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital. The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment. |
|
Experimental: Group 2. Experimental treatment.
Patients will be treated using a digitally supported physiotherapy programme.
|
A digitally supported physiotherapy programme including:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disabilities of the Arm, Shoulder and Hand Score (DASH)
Time Frame: 12 weeks
|
Global assessment of the functionality of the upper limb,
|
12 weeks
|
|
Disabilities of the Arm, Shoulder and Hand Score (DASH)
Time Frame: 3 months
|
Global assessment of the functionality of the upper limb,
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
European organization for research and treatment of cancer quality life questionnaire core 30. (QLQ-C30-B23)
Time Frame: 12 weeks
|
Questionnaire to assess quality of life in cancer patients.
Module B23, which is specific to breast cancer, will be used.
|
12 weeks
|
|
Range Of Motion (ROM)
Time Frame: 12 weeks
|
Goniometry of joint range
|
12 weeks
|
|
Tampa Scale for Kinesiophobia (TSK-11SV)
Time Frame: 12 weeks
|
The TSK is an 11-item self-report measure related to fear of movement and re-injury from movement.
|
12 weeks
|
|
Brief Pain Inventory (BPI)
Time Frame: 12 weeks
|
The BPI is a multidimensional pain assessment tool that provides information on pain intensity and its interference with patients' daily activities.
It also assesses the description, the location of pain and the level of relief provided by the treatment.
|
12 weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 weeks
|
Questionnaire to measure levels of anxiety and depression in these people.
|
12 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Hidding JT, Beurskens CH, van der Wees PJ, van Laarhoven HW, Nijhuis-van der Sanden MW. Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. PLoS One. 2014 May 9;9(5):e96748. doi: 10.1371/journal.pone.0096748. eCollection 2014.
- Pellini F, Granuzzo E, Urbani S, Mirandola S, Caldana M, Lombardi D, Fiorio E, Mandara M, Pollini GP. Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy. Breast Care (Basel). 2020 Feb;15(1):14-20. doi: 10.1159/000501711. Epub 2019 Sep 13.
- van Egmond MA, van der Schaaf M, Vredeveld T, Vollenbroek-Hutten MMR, van Berge Henegouwen MI, Klinkenbijl JHG, Engelbert RHH. Effectiveness of physiotherapy with telerehabilitation in surgical patients: a systematic review and meta-analysis. Physiotherapy. 2018 Sep;104(3):277-298. doi: 10.1016/j.physio.2018.04.004. Epub 2018 Jun 19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI-2021-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Active Comparator: Group 1. Conventional treatment
-
Riphah International UniversityCompletedCerebral PalsyPakistan
-
Assiut UniversityActive, not recruiting
-
University of AlcalaRecruitingTo be Approved by the Ethics CommitteeSpain
-
Francesca CecchiUniversity of Florence; Carol Davila University of Medicine and Pharmacy; Roessingh... and other collaboratorsNot yet recruitingSubacute Stroke | Stroke; SubacuteItaly
-
Ibadat International University, IslamabadRecruitingAthletic Performance | Postural Balance | Dynamic StabilityPakistan
-
Cardenal Herrera UniversityUniversity of Valencia; Clinica Universidad de Navarra, Universidad de NavarraCompletedChronic Low Back Pain (CLBP)Spain
-
Reistone Biopharma Company LimitedCompletedAtopic DermatitisChina, Canada
-
Mackay Medical CollegeNot yet recruitingBehavioral and Psychological Symptoms of Dementia
-
University of ExtremaduraActive, not recruitingOlder Adults, Balance | Postural Balance | Older Adult | Balance AssessmentSpain
-
Amsterdam UMC, location VUmcGE HealthcareNot yet recruiting